Welcome to our dedicated page for Equillium news (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium stock.
Equillium, Inc. (EQ) is a clinical-stage biotechnology company based in La Jolla, California, dedicated to developing innovative therapies for autoimmune and inflammatory disorders with significant unmet medical needs. Founded in 2017, Equillium has quickly established itself as a frontrunner in the biopharmaceutical industry through its focus on novel treatments that modulate the immune system.
The company’s primary product candidate is itolizumab, a unique monoclonal antibody targeting the immune checkpoint receptor CD6. Itolizumab is currently in advanced clinical trials, specifically a Phase 1b/2 trial for the treatment of acute graft-versus-host disease (aGVHD) and a Phase 1 trial for asthma and lupus nephritis. This promising treatment has shown potential in modulating immune responses and reducing inflammation, providing hope for patients suffering from severe autoimmune conditions.
In addition to itolizumab, Equillium's pipeline includes other groundbreaking therapies. EQ101 is a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15. EQ101 is Phase 2-ready and is expected to begin patient enrollment for an alopecia areata study in the second half of 2022. Another noteworthy drug is EQ102, a cytokine inhibitor that targets IL-15 and IL-21, which is also ready for clinical development and will soon begin enrolling patients in a Phase 1 trial, including those with celiac disease.
Equillium’s commitment to addressing immuno-inflammatory disorders is further demonstrated through its strategic partnerships and collaborations. These alliances have enabled the company to enhance its research capabilities, expedite clinical trials, and bring novel treatments to market more efficiently.
Financially, Equillium is well-positioned to continue its research and development activities. The company has secured funding through various channels, ensuring the advancement of its clinical programs. By focusing on diseases with high unmet needs and leveraging its unique approach to immune modulation, Equillium aims to deliver impactful therapies that improve patient outcomes and quality of life.
For the latest updates on Equillium, Inc., including recent achievements and ongoing projects, keep an eye on their official communications and news releases.
Equillium, Inc. (NASDAQ: EQ) presented positive results from its EQUATE study at the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation. The study analyzed the use of itolizumab combined with systemic corticosteroids in treating acute graft-versus-host disease (aGVHD). The findings showed significant clinical responses and improved progression-free survival rates over one year. Itolizumab demonstrated a favorable safety profile and may reduce corticosteroid usage by 99% within six months. Following this data, the pivotal Phase 3 EQUATOR study of itolizumab is underway, targeting first-line treatment of aGVHD, a condition with no approved first-line therapies.
Equillium, Inc. (Nasdaq: EQ) reported a cash balance of $71.0 million at the end of 2022, ensuring funding through 2025. The company acquired Bioniz Therapeutics, enhancing its pipeline with EQ101 and EQ102, both in clinical trials.
Equillium received $26.4 million upfront from a partnership with Ono Pharmaceutical, with an additional $139 million in potential milestone payments. Revenue for Q4 2022 reached $15.8 million, a significant increase from zero in 2021. However, the net loss for the full year was $62.4 million, up from $39.1 million in 2021. The company anticipates key clinical data releases in the second half of 2023.
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology firm, will present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30, at 10:30 am PT. The presentation will focus on the company's expertise in autoimmune diseases and its lead candidate, EQ101, a tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15, currently in a Phase 2 study for alopecia areata. Management will also be available for one-on-one meetings. A live webcast will be accessible on the company's website, with a replay available for 90 days.
Equillium, Inc. (Nasdaq: EQ) has announced positive results from its EQUATE study on Itolizumab, a targeted therapy for acute graft-versus-host disease (aGVHD). The presentation at the American Society of Transplantation and Cellular Therapy showed high clinical response rates with a 70% reduction in steroid use at Day 29 and a remarkable 99% taper at Day 169. These findings suggest potential for Itolizumab as a first-line treatment in severe aGVHD, with the initiation of the pivotal Phase 3 EQUATOR study.
Dr. Koreth emphasized the significance of these results, considering the lack of approved first-line treatments for aGVHD.
Equillium, Inc. (NASDAQ: EQ) announced its participation in the SVB Securities Global Biopharma Conference on February 14 at 10:00 am PT. The presentation will cover the recent partnership with Ono Pharmaceuticals and details on its multi-cytokine inhibitor platform, including EQ101 for alopecia areata and EQ102 for celiac disease. Management will also discuss upcoming catalysts and will be available for one-on-one meetings. The webcast can be accessed via the Investor Relations section of Equillium’s website, and a replay will be available for 90 days.
Equillium, Inc. (Nasdaq: EQ) announced that an abstract was accepted for oral presentation at the Transplantation & Cellular Therapy Meetings, taking place from February 15-19, 2023, in Orlando, Florida. The presentation, titled "Final Safety and Efficacy Results from EQUATE," details the promising findings of a Phase 1b study of itolizumab for treating newly diagnosed acute graft-versus-host disease (aGVHD).
The study shows significant outcomes, including long-term follow-ups up to one year. Following these results, Equillium has initiated EQUATOR, a Phase 3 study to evaluate itolizumab as a potential first-line treatment.
Equillium, Inc. (Nasdaq: EQ) and Metacrine, Inc. have mutually terminated their merger agreement, originally aimed at enhancing cash reserves. CEO Bruce Steel stated that a recent partnership with Ono Pharmaceutical will extend Equillium's financial runway into 2025, allowing focus on its pipeline of multi-cytokine inhibitors. The strategic shift emphasizes confidence in its clinical programs, including EQ101 and Itolizumab, which target severe autoimmune disorders. Further details can be found in Equillium's Current Report on Form 8-K.
Equillium, Inc. (NASDAQ: EQ) announced the initiation of a Phase 2 clinical study of itolizumab in collaboration with Biocon Limited for treating ulcerative colitis (UC) in India. This double-blinded, placebo-controlled trial aims to evaluate the safety and efficacy of itolizumab compared to adalimumab in biologics-naïve patients. The study will enroll up to 90 patients and is designed to provide insights into itolizumab's potential benefits. Itolizumab, a first-in-class anti-CD6 monoclonal antibody, has shown promise in earlier studies on severe acute graft-versus-host disease.
Equillium, Inc. (Nasdaq: EQ) announced positive interim results from the EQUALISE study of itolizumab in lupus nephritis, with 83% of patients achieving a complete or partial response and 67% showing over 80% reduction in urine protein creatinine ratio by week 28. The company also confirmed the acquisition of Metacrine, expected to add $35 million in cash to its balance sheet, extending its operating runway into 2024. Additionally, Equillium initiated Phase 2 and Phase 1 studies for EQ101 and EQ102, respectively, targeting alopecia areata and celiac disease.
FAQ
What is the current stock price of Equillium (EQ)?
What is the market cap of Equillium (EQ)?
What does Equillium, Inc. specialize in?
What is itolizumab?
What other products are in Equillium's pipeline?
Where is Equillium, Inc. headquartered?
When was Equillium, Inc. founded?
What are the current clinical trials for itolizumab?
What is the focus of EQ101?
What conditions is EQ102 targeting?
How is Equillium funded?
How can I stay updated on Equillium, Inc.'s latest news?
